Enanta Pharma says its EDP-297 Was Not Substantially Differentiated from EDP-305 Based on Phase 1 Results, Will Discontinue its ARGO-2 Trial Evaluating EDP-305 as a Monotherapy, Will Pursue Out-licensing Strategy Rather than Internal Development